STK24 and metabolic dysfunction-associated steatotic liver disease: Mice treated with antisense oligonucleotides (ASOs) targeting MST3 effectively ameliorated HFD-induced nonalcoholic fatty liver disease (NAFLD)-associated liver steatosis, inflammation, fibrosis, and hepatocellular damage [41].